 Home > Medical News > Latest Medical News > The review date of Legendary Bio's BCMA CAR-T cell therapy was postponed by the U.S. FDA for 3 months

The review date of Legendary Bio's BCMA CAR-T cell therapy was postponed by the U.S. FDA for 3 months

 Last Update: 2021-12-09
 Source: Internet
 Author: User

Tags

1 8 3 4

single pass

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Compilenewborn

Recently, the BCMA CAR-T cell therapy ciltacabtagene autoleucel (cilta-cel), jointly developed by Nanjing Legend Biotechnology and Johnson & Johnson’s Johnson Biotechnology, has encountered setbacks in the US supervision: FDA has extended the review timeline of cilta-cel by 3 Month

This is somewhat surprising.

The FDA postponed the review of cilta-cel because the agency has some questions about this CAR-T therapy, which will take time to resolve

Why postponed? The reason is somewhat vague

Nanjing Legend and Yang Sen met with the FDA on November 1

The marketing application of cilta-cel is based on an open-label Phase 1b/2 study, which enrolled patients with relapsed and/or refractory multiple myeloma (MM) who had previously tried 3 treatments

These data have attracted the attention of many MM experts

In March of this year, the BCMA CAR-T cell therapy Abecma from Bristol-Myers Squibb and Bluebird was approved by the US FDA, becoming the world's first BCMA CAR-T cell therapy to receive regulatory approval

Affected by the unfavorable news about cilta-cel supervision, the share price of Nanjing Legend fell nearly 9% in pre-market trading on the Nasdaq stock market on Tuesday morning

Reference source: Legend's status put on hold as FDA delays Janssen-partnered CAR-T decision

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.